A Longitudinal Analysis of IDO and PDL1 Expression During Immune- or Targeted Therapy in Advanced Melanoma

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2018 Jan 15

PMID 29331888

Citations 17

Authors

Lukas Krahenbuhl

Simone M Goldinger

Joanna Mangana

Katrin Kerl

Ines Chevolet

Lieve Brochez

Christine Horak

Mitch Levesque

Reinhard Dummer

Phil F Cheng

Affiliations

Soon will be listed here.

Abstract

A deepened understanding of the cellular and molecular processes in the tumor microenvironment is necessary for the development of precision immunotherapy (IT). We simultaneously investigated CD3, PDL1, and IDO by immunohistochemistry in paired biopsies from various organs of 43 metastatic melanoma patients treated with IT and targeted therapy (TT). Intraindividual biopsies taken after a period of weeks to months demonstrate discordant results in 30% of the cases. Overlap of IDO and PDL1 increased after therapy. IT only marginally impacted PDL1 expression over time in contrast to TT. Standardized repeated assessments of multiple immune markers in repeated biopsies will generate detailed insights in melanoma's immune evolution and adaption during therapies and might be used to support treatment decisions.

Citing Articles

Real-Life Outcomes of Adjuvant Targeted Therapy and Anti-PD1 Agents in Stage III/IV Resected Melanoma.

Roccuzzo G, Fava P, Astrua C, Brizio M, Cavaliere G, Bongiovanni E Cancers (Basel). 2024; 16(17).

PMID: 39272953 PMC: 11394626. DOI: 10.3390/cancers16173095.

The Aryl Hydrocarbon Receptor: Impact on the Tumor Immune Microenvironment and Modulation as a Potential Therapy.

Griffith B, Frankel T Cancers (Basel). 2024; 16(3).

PMID: 38339226 PMC: 10854841. DOI: 10.3390/cancers16030472.

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.

Della Corte C, Ciaramella V, Ramkumar K, Vicidomini G, Fiorelli A, Nardone V J Transl Med. 2022; 20(1):541.

PMID: 36419183 PMC: 9682755. DOI: 10.1186/s12967-022-03730-y.

Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors.

Naing A, Algazi A, Falchook G, Creelan B, Powderly J, Rosen S Cancer. 2022; 129(1):71-81.

PMID: 36309837 PMC: 10092291. DOI: 10.1002/cncr.34512.

Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors.

Marcelo-Lewis K, Moorthy S, Ileana-Dumbrava E J Immunother Precis Oncol. 2022; 3(3):121-127.

PMID: 35663256 PMC: 9165574. DOI: 10.36401/JIPO-20-6.

References

Phillips T, Simmons P, Inzunza H, Cogswell J, Novotny Jr J, Taylor C . Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol. 2015; 23(8):541-9. PMC: 4561627. DOI: 10.1097/PAI.0000000000000256. View

Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G . Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vii86-91. DOI: 10.1093/annonc/mds229. View

Tumeh P, Hellmann M, Hamid O, Tsai K, Loo K, Gubens M . Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017; 5(5):417-424. PMC: 5749922. DOI: 10.1158/2326-6066.CIR-16-0325. View

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23-34. PMC: 5698905. DOI: 10.1056/NEJMoa1504030. View

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Blank C, Haanen J, Ribas A, Schumacher T . CANCER IMMUNOLOGY. The "cancer immunogram". Science. 2016; 352(6286):658-60. DOI: 10.1126/science.aaf2834. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Robert C, Long G, Brady B, Dutriaux C, Maio M, Mortier L . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014; 372(4):320-30. DOI: 10.1056/NEJMoa1412082. View

Hoos A . Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016; 15(4):235-47. DOI: 10.1038/nrd.2015.35. View

10.

Speeckaert R, Vermaelen K, van Geel N, Autier P, Lambert J, Haspeslagh M . Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur J Cancer. 2011; 48(13):2004-11. DOI: 10.1016/j.ejca.2011.09.007. View

11.

Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D . Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology. 2006; 214(1):8-14. DOI: 10.1159/000096906. View

12.

Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E . PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017; 31(7):1633-1637. DOI: 10.1038/leu.2017.103. View

13.

. Genomic Classification of Cutaneous Melanoma. Cell. 2015; 161(7):1681-96. PMC: 4580370. DOI: 10.1016/j.cell.2015.05.044. View

14.

Brochez L, Chevolet I, Kruse V . The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur J Cancer. 2017; 76:167-182. DOI: 10.1016/j.ejca.2017.01.011. View

15.

Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G . Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v194-7. DOI: 10.1093/annonc/mdq188. View

16.

Cheng P, Dummer R, Levesque M . Data mining The Cancer Genome Atlas in the era of precision cancer medicine. Swiss Med Wkly. 2015; 145:w14183. DOI: 10.4414/smw.2015.14183. View

17.

Chevolet I, Speeckaert R, Haspeslagh M, Neyns B, Kruse V, Schreuer M . Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?. Br J Dermatol. 2014; 171(5):987-95. DOI: 10.1111/bjd.13100. View

18.

Spranger S, Spaapen R, Zha Y, Williams J, Meng Y, Ha T . Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013; 5(200):200ra116. PMC: 4136707. DOI: 10.1126/scitranslmed.3006504. View

19.

Ascierto P, Capone M, Urba W, Bifulco C, Botti G, Lugli A . The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med. 2013; 11:54. PMC: 3608225. DOI: 10.1186/1479-5876-11-54. View